Monitor the outcome of the November 6 special meeting; approval of Proposal 3 would authorize a significantly larger equity pool for future compensation, but the filing provides no current financial data to assess materiality.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Oct 28 $2.04entry
- T+1 · 6d ago −20.59%α −18.82% · $1.62
- T+5 · due 5h ago Pending
- T+5 · todayOpen
- T+20 · in 21d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
Jaguar Health filed an 8-K to supplement its proxy statement for the November 6, 2026 special meeting, disclosing a board-approved six-fold increase in the share reserve under the 2014 Stock Incentive Plan. The adjustment is intended to preserve the plan's proportional share count (targeting 14% of fully diluted shares) following a Series R Preferred Stock dividend that will convert into common shares at a 5:1 ratio on November 2, 2026. The filing is a routine proxy supplement with no material financial data or directional impact.
Key Facts
- Board unanimously approved a six-fold increase in shares available under the 2014 Stock Incentive Plan on October 28, 2026, effective after the special meeting.
- If Proposal 3 is approved, the plan will have 2,273,154 shares available (378,859 x 6); if not approved, 4,260 shares (710 x 6).
- The adjustment responds to a Series R Preferred Stock dividend declared October 2, 2026, with each preferred share converting into 5 common shares on November 2, 2026.
- The special meeting is scheduled for November 6, 2026, to vote on Proposal 3 (amending the 2014 Plan).
- Market cap is $18M; the filing contains no revenue, earnings, or financial results.
Financial Impact
No financial figures reported; the share reserve adjustment is administrative and contingent on stockholder approval.
Risk Factors
- Potential dilution if Proposal 3 is approved and the full 2,273,154 shares are issued under the plan.
- The Series R Preferred Stock conversion on November 2 will increase share count by up to 5x the preferred shares outstanding, adding further dilution.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-436334 |
| Document: 0001193125-26-436334-index-headers.html | 0001193125-26-436334 |
| Document: 0001193125-26-436334-index.html | 0001193125-26-436334 |
| Document: 0001193125-26-436334.txt | 0001193125-26-436334 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 3, 2026 today | S-3/A | $0.5599 | awaiting T+60 | awaiting T+60 | $0.4677 (+16.47%) |
Nov 3, 2026 today | 8-K | $0.5474 | awaiting T+60 | awaiting T+60 | $0.4677 (−14.56%) |
Oct 29, 2026 6d ago | DEFA14A | $2.04 | awaiting T+60 | awaiting T+60 | $0.4677 (+77.07%) |
Oct 28, 2026 6d ago | 8-K | $2.04 | awaiting T+60 | awaiting T+60 | $0.4677 (−77.07%) |
Oct 22, 2026 12d ago | S-3 | $2.04 | awaiting T+60 | awaiting T+60 | $0.4677 (+77.07%) |
Oct 8, 2026 26d ago | DEF 14A | $4.79 | awaiting T+60 | awaiting T+60 | $0.4677 (+90.24%) |
Oct 5, 2026 4w ago | 8-K | $4.73 | awaiting T+60 | awaiting T+60 | $0.4677 (+90.11%) |
Sep 28, 2026 5w ago | 8-K | $6.02 | awaiting T+60 | awaiting T+60 | $0.4677 (+92.23%) |
Sep 24, 2026 5w ago | SC 13G/A | $7.70 | awaiting T+60 | awaiting T+60 | $0.4677 (+93.93%) |
Sep 24, 2026 5w ago | 424B5 | $7.06 | awaiting T+60 | awaiting T+60 | $0.4677 (+93.38%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers